Otsuka Group News

Keyword search

Add search criteria

Search by company

Otsuka Holdings
Otsuka Pharmaceutical
Otsuka Pharmaceutical Factory
Taiho Pharmaceutical
Otsuka Warehouse
Otsuka Chemical
Otsuka Foods
Otsuka Medical Devices
Other

Search by category^*

Pharmaceuticals Business
Nutraceuticals Business
Consumer Products Business
Others
Products
R&D
Personnel
Corporate

* Business categories are based on the business segments described in the financial announcements.

Search by release date

-

Showing 104 results

Search by release date:: Jan, 2016 ～ Dec, 2016

December 22, 2016
Otsuka Medical Devices

Otsuka Medical Devices Announces Personnel Changes
December 21, 2016
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters into Health Promotion Partnership with Gunma Prefec
December 20, 2016
Otsuka Pharmaceutical

Akebia Therapeutics and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.
December 20, 2016
Otsuka Holdings

JSC High Performance Center Total Conditioning Research Project Joint research aims to promote sports medicine and science and boost international competitiveness
December 15, 2016
Otsuka Pharmaceutical

Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus
December 5, 2016
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters into Comprehensive Cooperative Partnership with Nara Prefecture
December 1, 2016
Otsuka Pharmaceutical

FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder
December 1, 2016
Otsuka Holdings

FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder
November 25, 2016
Otsuka Holdings

Otsuka Joins UN Global Compact
November 24, 2016
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters into Cooperative Agreements with Hokkaido Government Entities - Partnership Agreement for Promotion of Hokkaido Residents' Health Initiatives - - Cooperative Accord for Children's Education and Sports Promotion -
November 21, 2016
Otsuka Pharmaceutical

Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors Asan Walking Festival in Itano
November 18, 2016
Otsuka Pharmaceutical

New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan
November 18, 2016
Otsuka Pharmaceutical

ICLUSIG® Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
November 18, 2016
Taiho Pharmaceutical

Taiho and Meiji Announce the Launch of Bilanoa® Tablets 20 mg, an Oral Anti-allergy Drug in Japan
November 11, 2016
Otsuka Holdings

Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS)
November 10, 2016
Otsuka Pharmaceutical

Relationship between PMS/PMDD and production status of soy isoflavone metabolite equol Presentation to the Japan Society for Menopause and Women's Health
November 1, 2016
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters into Comprehensive Partnership with Hyogo Prefecture
October 31, 2016
Otsuka Pharmaceutical

Heatstroke Prevention Communication Project Hitosuzumi Awards 2016 Otsuka Pharmaceutical Named "Best Communicator" for Third Consecutive Year Proactive Efforts to Raise Awareness Also Recognized with "Top Runner Award"
October 28, 2016
Otsuka Pharmaceutical

POCARI SWEAT Recognized with Good Design Long Life Design Award
October 28, 2016
Otsuka Pharmaceutical

ORONAMIN C DRINK Recognized with Good Design Long Life Design Award
October 19, 2016
Otsuka Pharmaceutical

Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka's Subsidiary Astex Pharmaceuticals
October 18, 2016
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters into Disaster Support Agreement with Fukui Prefecture
September 28, 2016
Otsuka Pharmaceutical

ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
September 28, 2016
Otsuka Pharmaceutical

Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder
September 28, 2016
Otsuka Pharmaceutical

Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
September 28, 2016
Taiho Pharmaceutical

Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa® Tablets, an Oral Anti-allergy Drug in Japan
September 26, 2016
Otsuka Pharmaceutical

Headline conclusions from the phase III study of idalopirdine (Lu AE58054) for cognitive symptoms associated with Alzheimer's disease
September 26, 2016
Otsuka Pharmaceutical

U.S. FDA Approves Labeling Update of REXULTI®(brexpiprazole) for Maintenance Treatment of Schizophrenia in Patients in the U.S.
September 15, 2016
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters into Health Promotion Partnership with Yamanashi Prefecture
September 14, 2016
Otsuka Pharmaceutical

Announcement of Co-promotion of New Glaucoma Treatment